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Abstract Increased plasma levels of insulin-like growth
factor 1 (IGF-1) are observed in advanced arteriosclerosis,
but the reasons for these elevated levels remain unknown.
One possibility to explain them is variation in the
sequences that control IGF-1 gene expression. The goal of
this study was to determine the effect of molecular variants
of the IGF-1 P1 promoter on IGF-1 serum levels and to
determine the impact of IGF-1 levels on the severity of
coronary atherosclerosis. Methods: Blood samples were
collected from 101 consecutive patients undergoing routine
angiography. Genomic DNA was isolated from the nucle-
ated cells of the blood plasma as described (2). Based on
the presence of conformational differences in the DNA
strand and on the absence of single nucleotide polymor-
phisms, the DNA from 38 patients was further analyzed by
the ‘‘allelic ladder’’ method to determine the number of
repeated GC dinucleotides in the P1 promoter of the IGF-1
gene. In addition, we analyzed serum growth hormone
levels in order to examine the effect on systemic IGF-1
synthesis. Results: Conformational differences in the P1
promoter of the IGF-1 gene were observed in 38 out of the
101 patients. Several genotypes, depending on the number
of GC repeats, were observed (11/19,17/19,18/19,18/21,19/
19,19/20,19/21). Interestingly, a family history of coronary
artery disease was seen less often among individuals het-
erozygous for the GC repeats. A lower IGF-1 levels were
seen in non-variant carriers (homozygous genotypes for 19
or 21 repeats of GC, or heterozygous genotype 19/21)
when compared to the variant group (other heterozygous
genotypes then 19/21) (181.6 ± 47.9 ng/mL vs. 227.7 ±
73.7, p = 0.026). A correlation between IGF-1, IGF-
binding protein number 3, and growth hormone levels
(p = ns) was not observed, and there were no signiﬁcant
differences in the growth hormone levels in the studied
group of patients (p = ns).
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1 Introduction
IGF-1 affects the homeostasis of the vessel wall [1]. IGF-1
deﬁciency may precipitate the apoptosis of smooth muscle
cells migrating to the endothelial layer, as well as the cells
found in the media of the vessel. This probably contributes
to the destabilization of artherosclerotic plaque [2]. IGF-1
prevents the dilation of heart muscle by activating cardiac
progenitor cells and inhibiting apoptosis of cardiomyocytes
and VSMC hypertrophy [3]. The concentration of IGF-1
also increases in cases of acute ischaemia and is correlated
with the level of troponin [4]. This system is known as
PAAP (pregnancy plasma protein A)/IGF-1, and is
observed in early response to cardiac muscle ischaemia [4].
The role of insulin-like growth factor 1 (IGF-1) in the
progression of coronary atherosclerosis is unclear [1, 3, 5].
Further, little is known about the connection between tissue
protein levels of IGF-1, IGF-binding proteins (IGFBPs),
and their concentrations in the serum. In one of the few
studies addressing this subject [3], it was reported that low
systemic levels of IGF-1 and high systemic levels of IGF
binding protein-1 number 3 (IGFBP3) were a direct risk
factor for coronary artery disease, which has been further
conﬁrmed by the results of some prospective clinical
studies [4]. However, in a preliminary study, we found
signiﬁcantly higher levels of plasma IGF-1 in patients with
advanced coronary atherosclerosis (unpublished results).
These conﬂicting results leave the role of IGF-1 levels in
coronary atherosclerosis an unresolved question.
The possible impact of structural gene variation on
systemic levels of IGF-1 remains unknown. Two studies
suggest a relation between allele 192 nt (38 nt or repeat 19
in our study) and IGF-1 levels. This allele displays 19 GC
dinucleotides repeats in the IGF-1 P1 promoter sequence in
the region between -1,115 and -784 nt.
Our preliminary data has suggested that allelic diversity
in that region has a possible impact on advanced stages of
coronary artery disease [6]. However, this data was based
on an analysis of the promoter P1 region by SSCP and
TAG-polymerase sequencing techniques and did not allow
for an accurate evaluation of the length of the analysed P1
promoter region. The aim of this project was to determine
the inﬂuence of the GC repeats in the region between
-1,115 and -784 nt on plasma IGF-1 levels and the pro-
gression of coronary atherosclerosis in patients undergoing
routine coronary angiography.
2 Methods
2.1 Patient Selection
Patients were selected for the study if a coronary angiog-
raphy had been performed, as determined on the basis of an
exercise test and the presence of clinical symptoms of
coronary heart disease. The group of patients included 44
women and 57 men. Patients were excluded if they dis-
played acute coronary syndrome, myocardial infarction
during the preceding 3 months, acute congestive heart
failure (NYHA III/IV), acute or chronic hematopoietic
disease, cancer, acromegaly, or inﬂammation originating
from bacterial, viral, or fungal infections. The study pro-
tocol was approved by the local ethics committee.
2.2 Detection of Polymorphisms by SSCP
Blood samples were collected from 101 consecutive
patients, and DNA was isolated from the leukocytes with
DNA isolation kits. SSCP analysis was performed to detect
polymorphisms through differences in the migration of the
products on SDS–PAGE gels, and the results were veriﬁed
by the Sanger sequencing method, using Big Dye Termi-
nator kit v3.1 as described [6].
2.3 Allelic Ladder Technique
If the migration of DNA strands were altered in poly-
acrylamide electrophoresis (PAGE)-SSCP gels and no
mutations were evidenced by sequencing analysis, the
material was analysed by the DNA allelic ladder technique
to determine the exact number of GC dinucleotides repeats
in the region -1,115 to -784 in the P1 promoter of the
IGF-1 gene. Genomic DNA (20 ng) was ampliﬁed in a
30 lL reaction mix containing 7.5 pmol forward primer
(50-ACTTTCTTATCTACTGCTTCACAA-30), 7.5 pmol
reverse primer (50-ACCACTCTGGGAGAAGGGTA-30),
0.1 mM d-NTP, 1.5 mM MgCl2, 1 9 PCR buffer, and 1.2
U HiFi DNA polymerase (Novazym, Poland). The reac-
tions were performed in a 2,720 Thermal Cycler (Applied
Biosystems, USA) (94 C for 4 min; 30 cycles each at
94 C for 5 s; 55 C for 10 s, and at 60 C for 30 s; and a
ﬁnal extension at 65 C 30 min.) The reaction products
were gel puriﬁed using the kit QIAquick Gel Extraction Kit
(Qiagen, Japan) and subcloned into EasyVector pGEM-T
(Promega, USA). Recombinant plasmids were isolated and
sequenced to determine the number of repeated GC dinu-
cleotides. Sequencing reactions were carried out using the
BigDye Terminator 3.1 kit (Applied Biosystems, USA)
according to manufacturer’s guidelines. The sequences
were read automatically with ABI 3,1309l. Selected
plasmids were used as matrices for the separate
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123ampliﬁcation of amplicons labeled with FAM. PCR was
carried out in 15 ll reactions with approximately 5 ng
plasmid DNA, 2.25 pmol forward primer (50-AAGAAAA
CACACTCTGGCAC -30) labeled with FAM, 2.25 pmol
reverse primer (50-ACCACTCTGGGAGAAGGGTA-30),
0.1 m mM d-NTP, 1.5 mM MgCl2 buffer, and 0.6 U
19PCR HiFi DNA polymerase (Novazym, Poland). The
reaction was performed in a 2,720 thermal cycler (Applied
Biosystems, USA) (94 C for 4 min; 25 cycles each of
94 C for 5 s and 60 C for 30 s; and a ﬁnal extension at
65 C for 30 min.) PCR products were collected in the
form of allelic ladders and analysed in an apparatus for
automated sequencing ABI 3,1309l with internal standard
size GS600LIZ (Applied Biosystems, USA).
2.4 Determination of IGFPB3, IGF-1, and GH Levels
The serum concentrations of IGFBP3 and IGF-1 were
estimated by radioimmunoisotopic and radioisotopic assays
using reagents from BioSource (Nivelles, Belgium) [6].
GH serum levels were estimated using commercially
available ELISA kits (DRG International, USA).
3 Results
Test groups were homogenous in terms of basic clinical
parameters (Tables 1, 2, 3). SSCP analysis detected poly-
morphisms in the region between -1,115 and -784 in the
P1 promoter of the IGF-1 gene in 38 of the 101 patients.
Each SSCP was established by differences in the migra-
tional speed of the DNA strands in PAGE and by the
absence of any mutation as shown by sequencing analysis
[6]. Among these 38 patients, a large number of genotypes
were present based on the number of GC repeats (Table 4).
Twenty-ﬁve patients were heterozygotes and 13 were
homozygotes. The remaining 63 patients were previously
found to be homozygotes based on SSCP and sequencing
analysis [6]. There were no statistically signiﬁcant differ-
ences in the IGF-1 plasma levels between the homozygous
(due to most frequent genotype 19/19, N = 76) and het-
erozygous group (genotypes 11/19, 17/19, 18/19, 18/21,19/
20,19/21, N = 25). However, heterozygotes notably had a
less frequent family history of coronary artery disease
(CAD; p = 0.00015). There were no signiﬁcant differences
between groups with regard to severity of atherosclerosis or
past heart attacks.
Based on a protocol established by Yazdanapah [7],
different genotypes were assigned to two groups: Group 1
consisted of non- variant carriers (homozygotes due to 19
GC cassette replicates or homozygotes to 21 cassettes GC
replicates or heterozygous 19-rep/21-rep i.e. 38 nt/42 nt.
Group 2 consisted of variant carriers (heterozygous
genotypes other then genotype 19/21). In group 2, higher
plasma levels of IGF-1 were observed relative to those in
group 1 (227.7 ± 73.7 ng/mL vs. 181.6 ± 47.9 ng/mL,
p = 0.026). Unfortunately, the low number of subjects
within each group prevented a statistical evaluation in
regards to the severity of atherosclerosis, family history of
CAD, or past myocardial infarction. A correlation between
IGF-1, IGFBP3 and growth hormone (p = ns) was not
observed, nor were there any signiﬁcant differences in
growth hormone levels (p = ns).
4 Discussion
Grant et al. [8] was the ﬁrst publication to report lack of
IGF-1 expression in normal coronary arteries and its
overexpresion in post-atherectomy specimens. Jansen [9]
associated high serum IGF-1 levels with decreased preva-
lence of CAD.
Despite these observations, it was found that the extent
of myocardial infarction correlates with elevated systemic
concentrations of IGF-1 and GH [10] within a few days
after an acute coronary syndrome, especially among people
who die a few months after myocardial infarction [11, 12].
One interpretation is that these increased levels may reﬂect
the anti-apoptotic properties of IGF-1 and GH and hence
prevent the adverse post-infarction remodelling of the left
ventricle [13].
Because of how little is known about the process, it is
still difﬁcult to draw conclusions about the mechanism that
might account for the signiﬁcantly higher levels of IGF-1
in patients with advanced coronary atherosclerosis (pre-
liminary data). However, several different hypotheses can
be advanced. First, elevated levels of GH could account for
the increased levels of IGF-1. However, this explanation is
unlikely because IGF-1 levels did not correlate with the
level of GH. Indeed, all study participants displayed nor-
mal GH levels (\7 ng/mL). Second, the elevated plasma/
serum IGF-1 levels could be the result of increased
expression of proteases releasing IGF-1 from the ternary
complex (IGF-1 ? IGFBP3 ? acid-labile protein), which
is also secreted in response to ischeamia [3]. Third, an
increase in hepatic IGF-1 gene expression under the
inﬂuence of inﬂammatory mediators or variability in the
regulatory sequences responsible for its expression.
Before testing any of these hypotheses, we ﬁrst wanted
to determine the impact of a single genetic variant, which
can inﬂuence IGF-1 synthesis and the prognosis for
patients with a family history of CAD. While the IGF-1
protein-coding sequence is highly conserved, the promoter
is highly variable. One of its molecular variants, described
in a large-population Rotterdam Study, contains a different
number of GC nucleotide repetitions in the region between
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123-1,115 and -784 nt. Our preliminary data [6] showed a
lower incidence of advanced coronary atherosclerosis in
patients with the SSCP in this region of the P1 promoter.
Further molecular analysis was used to determine the exact
number of GC repeats in 38 cases, and the ﬁndings were
conﬁrmed only in 25 patients. There were no signiﬁcant
differences in IGF-1 levels, in the degree of coronary
atherosclerosis, or in the MI history between patients who
were homozygous and those who were heterozygous for
the GC repeats. Only the rare occurrence of the familial
CAD load in the group of heterozygotes may partially
conﬁrm our preliminary ﬁndings [6].
Table 1 Characteristics of
group with conformational
differences in region between -
1,115 and -784 in the P1
promoter of the IGF-1 gene
divided into variant carriers and
non variant carriers according to
the GC repeats estimation
ApoA1 apoprotein A1, ApoB100
apoprotein B-100, BMI body
mass index, HDL,LDL
lipoproteins, IGF insulin like
growth factor, Lp(a) lipoprotein
a, TC total cholesterol, IGFBP3
IGF binding protein number 3
Parameters Variant carriers Non variant carriers All subjects with observed
conformational differences
in region between -1,115
and -784 in the P1 promoter
of the IGF-1 gene
Mean ± SD (N = 12) Mean ± SD (N = 26) Mean ± SD (N = 38)
Weight (kg) 85.8 ± 15 78.8 ± 14.0 81 ± 14.5
Height (cm) 170.1 ± 7.8 163.9 ± 9.4 165.9 ± 9.3
BMI (kg/m
2) 29.8 ± 5.9 29.1 ± 3.8 29.3 ± 4.5
TC (mg/dL) 198.2 ± 53.2 202.2 ± 56.6 201 ± 54.8
HDL (mg/dL) 44.8 ± 11.2 52.0 ± 13.3 49.7 ± 13.0
LDL (mg/dL) 124.8 ± 43.8 122.6 ± 50.1 123.3 ± 47.6
Lp(a) (g/L) 0.12 ± 0.14 0.19 ± 0.24 0.17 ± 0.22
Apo B-100 [g/L] 1.02 ± 0.31 1.1 ± 0.32 1.04 ± 0.31
Apo A1(g/L) 1.46 ± 0.2 1.57 ± 0.23 1.5 ± 0.2
IGF/BMI 8.1 ± 3.6 6.3 ± 1.9 6.9 ± 2.66
IGF-1 (ng/mL) 227.6 ± 73.7 181.6 ± 47.9 196 ± 60.3
IGFBP3 (ng/mL) 2,092.6 ± 721.3 2,081.7 ± 504.5 2,085.2 ± 653.7
Diabetes mellitus (%) 13.16 23.68 36.84
Smoking cigaretes (%) 13.16 7.89 21.05
Hypertension (%) 23.68 50 73.68
Table 2 Basic parameters in all consecutive patients scheduled for routine coronary-angiography
Parameters Mean value ± SD
in female group (N = 44)
Mean value ± SD
in male group (N = 57)
Mean value ± SD in
all examined patients
(N = 101)
Weight (kg) 72.7 ± 14 82.8 ± 13.83 78.47 ± 14.7
Height (cm) 159.2 ± 6.92 171.57 ± 6.67 166.3 ± 9.12
BMI (kg/m
2) 28.57 ± 4.52 28.07 ± 4.05 28.28 ± 4.24
TC (mg/mL) 198.7 ± 55.14 191.46 ± 47.88 194.6 ± 50.97
HDL (mg/mL) 53.31 ± 16.32 45.21 ± 13.58 48.68 ± 15.28
LDL (mg/mL) 116.59 ± 48.3 119.21 ± 41.65 118.1 ± 44.37
TG (mg/mL) 144.26 ± 59.12 144.21 ± 79.99 144.2 ± 71.46
Lp (a) (g/L) 0.179 ± 0.233 0.14 ± 0.18 0.162 ± 0.2
Apo B-100 (g/L) 1.006 ± 0.376 1.01 ± 0.29 1.008 ± 0.33
Apo AI (g/L) 1.621 ± 0.261 1.46 ± 0.22 1.532 ± 0.25
IGF-1/BMI 6.571 ± 1.912 7.57 ± 2.57 7.147 ± 2.35
IGF-1 (ng/mL) 183.71 ± 47.25 207.91 ± 61.88 197.5 ± 57.1
IGFBP3 (ng/mL) 2,210.9 ± 675.9 2,021.6 ± 623.13 2,102.7 ± 649.74
Hypertension (%) 78.6 62 69
Diabetes mellitus (%) 28.6 21 24.5
Smoking cigaretes (%) 11.9 30 22.4
ApoA1 apoprotein A1, Apo B100 apoprotein B-100, BMI body mass index, HDL,LDL lipoproteins, IGF insulin like growth factor, Lp(a)
lipoprotein a, TC total cholesterol, TG triglicerydesl, IGFBP3 IGF binding protein number 3
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123In the current study, due to large diversity of observed
genotypes, we additionaly created two groups (following
Yazdanapah). First group contains ‘‘non variant’’ subjects
and second one, individuals carrying ‘‘variant’’. Although
the variant carriers showed signiﬁcantly higher levels of
IGF-1(in opposition to Yazdanapah), the number of cases
of previous myocardial infarction and the severity of
coronary atherosclerosis (estimated by the number of sig-
niﬁcant narrowing lesions in coronary arteries) were sim-
ilar between both groups. Therefore, we can conﬁrm
previous two literature observations that polimorphism
associated with different number of GC nucleotide repeti-
tions in the region between -1,115 and -784 nt has an
impact on the systemic IGF-1 pool, yet it remains an
unresolved issue whether the frequency of its various
genotypes in the general population will indeed have an
inﬂuence on and correlate with the severity of ischaemic
heart disease. In view of that, it seems that our conclusions
do not account for the phenomenon of statistically signif-
icant elevated IGF-1 levels, nor do they explain the role of
IGF-1 in patients with an advanced form of stable ischae-
mic heart disease, as it is difﬁcult to imagine that the local
synthesis of IGF-I in the coronary vessel wall could
increase systemic levels of this protein to such high levels.
One can only speculate that the increased pool of systemic
IGF-1, caused by an unknown mechanism, protects against
the adverse consequences of plaque rupture.
The indisputable limitations of our study were the small
number of participants and the uncertainty arising from the
angiographic examination itself (i.e. no possibility of ver-
ifying the processes taking place in the coronary vessel
wall). In addition, the technique for assessing the number
of GC repeats was employed only in the 38 cases where the
SSCP was observed. Thus, only 13 homozygotes with
respect to the 38 nt allele were conﬁrmed by the allelic
ladder technique. The remaining 63 other patients were
also homozygous, but the utilised SSCP technique could
not identify the exact number of GC repetitions. Therefore,
we assumed that they were carriers of allele 38/38 nt. This
assumption is founded on two facts. First, it was the only
homozygous genotype found in the studied population,
which was additionally conﬁrmed in all 63 cases by the
DNA strands in a polyacrylamide gel migrating at the same
rate. Secondly, the results of sequencing the P1 promoter
fragment showed no mutational variations, as described in
[6]. Therefore, it appears that the applied procedure was
sufﬁcient to exclude polymorphisms, and only the dis-
crepancy between the results of SSCP and sequencing
required further molecular veriﬁcation, which has been
done.
5 Conclusions
The presence of variants in the study population is asso-
ciated with signiﬁcantly higher levels of systemic IGF-1.
Among individuals heterozygous for GC repeats, the
family CAD was less frequent. The veriﬁcation of obser-
vations concerning the relationship of IGF-1 with the
advanced atherosclerotic process is likely to be possible
Table 3 Characteristics of groups divided into most frequent geno-
types due to the GC repeats estimation
Parameters Heterozygous genotypes
(11/19, 17/19, 18/19,19/
20, 19/21, Mean ± SD
N25
Homozygous
genotype 19/19
(most frequent
in analysis)
Mean ± SD N74
Weight (kg) 80.01 ± 15 77.8 ± 14.6
Height (cm) 166.6 ± 9.3 164.9 ± 9.05
BMI (kg/m
2) 29.4 ± 4.9 27.9 ± 3.9
TC (mg/dL) 188.1 ± 55.05 197.27 ± 49.2
HDL (mg/dL) 48.25 ± 13.7 48.25 ± 13.7
LDL (mg/dL) 110.7 ± 45.5 121.1 ± 43.4
Lp(a) (g/L) 0.14 ± 0.15 0.16 ± 0.21
Apo B-100 (g/L) 0.99 ± 0.26 1.01 ± 0.34
Apo A1 (g/L) 1.5 ± 0.25 1.5 ± 0.25
IGF/BMI 7.0 ± 3.1 7.2 ± 2.05
IGF-1 (ng/mL) 195.3 ± 68.9 199.2 ± 55
IGFBP3 (ng/mL) 1,987.04 ± 676.9 2,151.8 ± 641.83
Diabetes mellitus (%) 41.6 18.9
Smoking cigaretes
(%)
29.17 21.05
Hypertension (%) 75 67.11
ApoA1 apoprotein A1, Apo B100 apoprotein B-100, BMI body mass
index, HDL,LDL lipoproteins, IGF insulin like growth factor, Lp(a)
lipoprotein a, TC total cholesterol, IGFBP3 IGF binding protein
number 3
Table 4 Frequency of genotypes in studied population
Genotypes according
to the number of
repeated GC dinucleotides
between -1,115 and
-784 nt in p1 promoter
of IGF-1 gene
Frequency of
genotypes in
examined
population N
Frequency of
genotypes in
examined
population N %
Genotype 19\21 (19/21
repeats of GC)
13 12.87
Genotype 19\19
a 76 75.25
Genotype 18\19 3 2.97
Genotype 19\20 6 5.94
Genotype 11\19 1 0.99
Genotype 17\19 1 0.99
Genotype 18\21 1 0.99
a 63 cases due to observed SSCP, 13 cases conﬁrmed by allelic ladder
528 P. Burchardt et al.
123only after the exclusion of molecular variation within the
entire P1 promoter gene and the receptor gene for IGF-1.
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